Global Anti Obesity Prescription Drugs Market

Anti-Obesity Prescription Drugs Market was valued at USD 2.97 Bn. in 2024 and the total Global Anti-Obesity Prescription Drugs Market revenue is Expected to grow at a CAGR of 4.9% from 2025 to 2032 reaching nearly USD 4.35 Bn. by 2032.

According to past study 650 Mn individuals in 1965 had corpulent body and recent study data shows the obesity has tripled in 2023, giving a number of 1.6 Bn individuals who are suffering from overweight problems. A corpulent individual is at a higher risk of developing chronic diseases like endometrial cancer, breast cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.

To know about the Research Methodology :- Request Free Sample Report

The drug which inhibit fat absorption, energy intake, enhance energy expenditure and stimulate fat mobilization are known as Anti-Obesity Drugs. The FDA has approved five different types of Anti-Obesity Prescription Drugs lorcaserin (Belviq), orlistat (Xenical), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and liraglutide (Saxenda).Global Anti-Obesity Prescription Drugs Market Drivers and RestrainsThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

According to, Disease Control & Prevention Centers show that 68.8% of the United State population is obese. The increasing incidence of the condition is followed by growing awareness of the same. Because of, the increasing awareness of anxiety that customers shift to anti-obesity drugs is rising at a prominent step. Obesity can be credited as an incurable chronic disease that increases the risk of cardiovascular diseases like diabetes, hypertension, and strokes. Sometimes, lifestyle intervention fails to impart potential results and a huge proportion of patients obvert their customary standards to enhance positive clinical outcome with the consumption of prescribed weight loss drugs.

Advanced technique of skin patch delivery that permits for the administration of anti-obesity prescription drugs with low risk of side effects. Furthermore, the development of Nano Soy-Phytosome based thermo gels as the interesting formulations of anti-obesity is a key novelty in the market. Herbal supplements are the recent trend in the anti-obesity prescription drugs market. These trends are expected to boost opportunities for the growth of sellers in the global anti-obesity drugs market. The top Food and Drug Administration (FDA) approved anti-obesity drugs are Contrave, Belviq, Xenical, Saxenda and Qsymia. In United State, Xenical was the largest selling drug in the market until 2012, because of the character for unpleasant gastrointestinal side effects showed by Xenical. Though, recently approved Saxenda by Novo Nordisk Pharma is gaining large interest between obese individuals and is growing at a unanimous rate.

Manufacturers in the Anti-Obesity Prescription Drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Segment Analysis

Based on the Drug type the Anti-Obesity Prescription Drugs Market is segmented into Contrave, Belviq, Xenical, Saxenda and Qsymia. Saxenda segment dominated the market in 2024 and is expected to hold largest share during the forecast period. Saxenda, a GLP-1 receptor agonist, gained strong adoption due to its high efficacy in weight management, ability to improve metabolic health, and proven clinical outcomes compared to other drugs. Rising obesity prevalence, physician preference for GLP-1 therapies, and favorable reimbursement policies further boosted demand. Its dual benefits of weight reduction and diabetes risk management made it the most widely prescribed option.

Based on the Application the Market is Segmented into Hospitals Pharmacies, Retail Pharmacies and E-commerce. Hospital Pharmacies dominated the market in 2024 and is expected to hold largest share during the forecast period. Hospitals serve as the primary channel for prescribing and dispensing anti-obesity and weight management drugs, as they are directly linked with physician consultations and patient monitoring. The strong trust factor, immediate availability of prescribed medications, and integration with treatment plans give hospital pharmacies an advantage over retail and e-commerce channels, making them the largest contributor to overall market revenue.

Regional Insights

In terms of regional analysis North America is expected to emerge as a leading region in the global anti-obesity prescription drugs market during the forecast period. Because of the awareness of obesity among the population and the risks associated with the health situation have resulted in the anti-obesity prescription drugs market describing flourished growth in the region over the years. The Asia Pacific market for anti-obesity prescription drugs is anticipated to drive in the coming years, thanks to the rise in obese population. The European Medicines Agency (EMA), retreated the utilization of a series of anti-obesity drugs attributed to prohibited proportion of threat to benefit ratio, in 2000. Anti-obesity prescriptive drug like Rimonabant was available in more than 55 countries Afterward, in the year 2009 Rimonabant was withdrawn from the European anti-obesity prescription drugs market due to serious psychiatric side effects. In recent times, numerous development have been tested and examined, but only orlistat and sibutramine have been permitted for long-term use.

The objective of the report is to present comprehensive analysis of Global Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Market dynamics, structure by analyzing the market segments, and project the Global Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.

Anti-Obesity Prescription Drugs Market Scope: Inquire before buying

Anti-Obesity Prescription Drugs Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Anti-Obesity Prescription Drugs Market, Key Players

1. F Hoffmann La Roche
2. Arena Pharmaceuticals
3. Orexigen Therapeutics
4. Phentermine and Topiramate
5. VIVUS, Inc
6. Liraglutide
7. Bupropion and Naltrexone
8. Orlistat
9. Novo Nordisk
10.Lorcaserin
11.GlaxoSmith Kline
12.Eisai Co, Ltd
13.Boehringer Ingelheim
14.Merck & Co
15.Pfizer
16.Rhythm Pharmaceuticals
17.Zafgan
18.Takeda Pharmaceuticals
19.Novo Nordisk
20.Bristol-Myers Squibb Co.
21.Shionogi USA Inc
22.Norgine by

Frequently Asked Questions:

1.Which region has the largest share in Global Anti-Obesity Prescription Drugs Market?
Ans: North America region held the highest share in 2024.

2.What is the growth rate of Global Anti-Obesity Prescription Drugs Market?
Ans: The global market is growing at a CAGR of 4.9% during forecasting period 2025-2032.

3.What is scope of the Global Anti-Obesity Prescription Drugs market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4.Who are the key players in Global market?
Ans: The important key players in the global market are – Phentermine and Topiramate, VIVUS, Inc, F Hoffmann La Roche, Liraglutide, Norgine bv, Bupropion and Naltrexone, Orlistat, Novo Nordisk, Lorcaserin, GlaxoSmith Kline, Eisai Co, Ltd, Boehringer Ingelheim, Merck & Co, Pfizer, Rhythm Pharmaceuticals, Zafgan, Takeda Pharmaceuticals, Novo Nordisk, Bristol-Myers Squibb Co., and Shionogi USA Inc.

5. What is the study period of this market?
Ans: The Global Market is studied from 2024 to 2032.